CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis

Leukemia Research

Volumn 32, Issue 3, 2008, Pages 379-382

  Bataille, Régis ^a   Pellat Deceunynck, Catherine ^a   Robillard, Nelly ^a   Avet Loiseau, Hervé ^a   Harousseau, Jean Luc ^b   Moreau, Philippe ^b  

^a INSTITUT DE BIOLOGIE   (France)

^b HÔTEL DIEU   (France)

Author keywords

CD117; Myeloma

Indexed keywords

ANTIGEN; BETA 2 MICROGLOBULIN; CD 221 ANTIGEN; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; RECURRENT DISEASE; SURVIVAL;

AGED; CELL LINE, TUMOR; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; SURVIVAL ANALYSIS;

EID: 39749118895     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.07.016     Document Type: Article

References (21)

1. Miettinen M., and Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 13 (2005) 205-220
2. Ocqueteau M., Orfao A., Garcia-Sanz R., Almeida J., Gonzalez M., and San Miguel J.F. Expression of the CD117 antigen (c-kit) on normal and myelomatous plasma cells. Br J Haematol 95 (1996) 489-493
3. Attal M., Harousseau J.L., Stoppa A.M., Sotto J.J., Fuzibet J.G., Rossi J.F., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335 (1996) 91-97
4. Attal M., Harousseau J.L., Facon T., Guilhot F., Doyen C., Fuzibet J.G., et al. Single versus double transplant in myeloma: a randomised trial of the IFM. N Engl J Med 349 (2003) 2495-2502
5. Robillard N., Pellat-Deceunynck C., and Bataille R. Phenotypic characterization of the human myeloma cell growth fraction. Blood 105 (2005) 4845-4848
6. Robillard N., Avet-Loiseau H., Garand R., Moreau P., Pineau D., Rapp M.J., et al. The expression of CD20 is aberrant, significantly associated with a small mature plasma-cell morphology, t(11;14) and good survival in multiple myeloma. Blood 102 (2003) 1070-1071
7. Bataille R., Robillard N., Avet-Loiseau H., Harousseau J.L., and Moreau P. CD221 (IGF1-R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica 90 (2005) 706-707
8. Avet-Loiseau H., Facon T., Grosbois B., Magrangeas F., Rapp M.J., Harousseau J.L., et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 99 (2002) 2185-2191
9. Moreau P., Facon T., Leleu X., Morineau N., Huyghe P., Harousseau J.L., et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive therapy. Blood 100 (2002) 1579-1583
10. Ocqueteau M., Orfao A., Almeida J., et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 152 (1998) 1655-1665
11. Potti A., Ganti A.K., Koch M., Levitt R., and Mehdi S.A. Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma. Leuk Lymphoma 43 (2002) 2427-2430
12. Bayer-Garner I.B., Schwartz M.R., Lin P., and Smoller B.R. CD117, but not lysozyme, is positive in cutaneous plasmacytoma. Arch Pathol Lab Med 127 (2003) 1596-1598
13. Li J., Luo S.K., Zhang G.C., Hong W.D., and Tong X.Z. Expression of CD117 on multiple myeloma and its significance. Ai Zheng 23 (2004) 951-954
14. Lugli A., Went P., Khanlari B., Nikolova Z., and Dirnhofer S. Rare kit (CD117) expression in multiple myeloma abrogates the usefulness of imatinib mesylate treatment. Virchows Arch 444 (2004) 264-268
15. Kraj M., Poglod R., Kopec-Szlezak J., Sokolowska U., Wosniak J., and Kruk B. c-Kit receptor (CD117) expression on plasma cells in monoclonal gammopathies. Leuk Lymphoma 45 (2004) 2281-2289
16. Pruneri G., Ponzoni M., Ferreri A.J., et al. The prevalence and clinical implications of c-kit expression in plasma cell myeloma. Histopathology 48 (2006) 529-535
17. Dispenzieri A., Gertz M.A., Lacy M.Q., Geyer S.M., Greipp P.R., Rajkumar S.V., et al. A phase II trial of imatinib in patients with refractory/relapsed myeloma. Leuk Lymphoma 47 (2006) 39-42
18. Rawstron A.C., Fenton J.A.L., Gonzalez D., Davies F.E., O'Connor S.J.M., Richards S.J., et al. Accurate prediction of outcome for with IgG and IgA monoclonal gammopathy of unknown significance patients using flow cytometry. Haematologica 90 S1 (2005) 196
19. Mateo G., Castellanos M., Rasillo A., et al. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res 11 (2005) 3661-3667
20. Chang W.J., Van Wier S.A., Ahmann G.J., et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 106 (2005) 2156-2161
21. Mateo G., Mateos M.V., Rosinol L., Montalban M.A., Lopez-Berges C., Bladé J., et al. Prognostic influence of antigenic markers in 587 multiple myeloma patients uniformly treated with high dose therapy. Haematologica 90 s1 (2005) 103